Walt Piskorski is a chemical engineer and manager with extensive experience in all aspects of commercializing drug development. Most recently, as COO of Neurovance/Euthymics, a Cambridge, MA start-up, he was closely involved in fund raising as well as clinical operations management. He also played an integral role in all business development activities focused on acquiring additional funding as well as selling the company. In addition to directing various drug substance/product development and manufacturing efforts, he also is experienced in the M&A side of the pharma business. As Director of Business Development at Armstrong Pharmaceuticals, he directed the team that not only developed the first US based albuterol MDI generic inhaler, but also managed all M&A activities culminating in the sale of Armstrong to Medeva Ltd. He was a key member of the Sepracor team that developed/launched four NDA products – Xopenex, Lunesta, Xopenex HFA, and Brovana and managed their growth from $0 to $1.2Billion.